Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate 09:08:21 2024-06-24 am EDT 5-day change 1st Jan Change
28.22 EUR +0.55% Intraday chart for Fresenius SE & Co. KGaA -4.05% +0.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
New version of clinic atlas available DP
Hospital atlas to be slimmed down DP
Clinic atlas to become easier to understand - update in a few days DP
NRW hospital association expects cuts due to clinic reform DP
Health Minister Lauterbach sees hospital reform on the right track DP
FRESENIUS SE : Buy rating from Deutsche Bank ZD
Barclays Lifts Fresenius PT, Maintains Overweight Rating MT
FRESENIUS SE : Buy rating from Jefferies ZD
FRESENIUS : Barclays remains positive after a CMD CF
Optimism gives Dax a tailwind RE
FRESENIUS SE : JP Morgan gives a Neutral rating ZD
Dpa-AFX Overview: COMPANIES from 05.06.2024 - 15:15 DP
FRESENIUS SE : Berenberg reiterates its Buy rating ZD
FRESENIUS SE : Barclays reaffirms its Buy rating ZD
Fresenius raises targets for hospital business - shares up DP
FRESENIUS SE : Jefferies reaffirms its Buy rating ZD
Fresenius raises the bar for hospital subsidiary Helios RE
Fresenius driven by higher Helios targets DP
FRESENIUS SE : Jefferies gives a Buy rating ZD
Transcript : Fresenius SE & Co. KGaA - Analyst/Investor Day
Fresenius lifts 2024 targets for private healthcare unit Helios RE
Fresenius chart breakout fails before capital market day DP
Austria's state holding ÖBAG sells stake in Vamed to Fresenius RE
FMC briefly burdened by research success in the fight against diabetes DP
FMC, Fresenius and Davita rise after Ozempic news DP
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
28.07 EUR
Average target price
37.26 EUR
Spread / Average Target
+32.73%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability